The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue British Journal of Dermatology Année : 2023

The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma

Résumé

BACKGROUND: Proton-pump inhibitors (PPIs) are commonly used by patients with cancer, although they could reduce the absorption of oral anticancer targeted therapies. The US Food and Drug Administration states that the effect of PPIs on the efficacy of dabrafenib use by patients with metastatic melanoma is unknown. As a precautionary measure, the European Society for Medical Oncology recommends avoiding PPIs for patients receiving dabrafenib. OBJECTIVES: To determine the effect of the concomitant use of PPIs and BRAF/MEK inhibitors in patients with metastatic melanoma.METHODS: Patients with advanced melanoma receiving BRAF/MEK inhibitors as first-line treatments between 2015 and 2017 in France were selected using the French National Health Insurance database. We compared time-to-treatment discontinuation (TTD) and overall survival (OS) according to concomitant PPI exposure. We balanced the baseline characteristics of patients exposed and nonexposed to PPIs using an overlap weighting method based on a propensity score.RESULTS: The metastatic melanoma cohort comprised 1028 patients receiving BRAF/MEK inhibitors, including 361 (35.1%) patients using PPIs. PPI users had more comorbidities and a more severe metastatic disease. After having equally distributed metastatic sites and comorbidities across patients exposed and nonexposed to PPIs, concomitant PPI use was not associated with shorter TTD [weighted hazard ratio (wHR) 1.03, 95% confidence interval (CI) 0.86-1.24] or OS (wHR 1.11, 95% CI 0.88-1.39). Consistent results were observed when restricting the population to patients receiving dabrafenib, or when narrowing exposure to PPIs with stronger inhibition of cytochromes.CONCLUSIONS: In a population-based cohort of patients with advanced melanoma, the concomitant use of PPIs and BRAF/MEK inhibitors was not associated with worse outcome.
Fichier principal
Vignette du fichier
Poizeau et al-2023-The concomitant use of proton pump inhibitors and BRAF MEK inhibitors in metastatic melanoma .pdf (1.08 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Licence : CC BY NC - Paternité - Pas d'utilisation commerciale

Dates et versions

hal-04013531 , version 1 (05-05-2023)

Identifiants

Citer

Florence Poizeau, Frederic Balusson, Florian Lemaitre, Camille Tron, Marc Pracht, et al.. The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma. British Journal of Dermatology, 2023, 188 (4), pp.482-490. ⟨10.1093/bjd/ljac085⟩. ⟨hal-04013531⟩
50 Consultations
37 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More